Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
ID: 339281Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" aimed at establishing population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship. This initiative specifically seeks to support methodological development for participant recruitment and retention, with an emphasis on including understudied populations and fostering community engagement. The grant is part of NIH's commitment to advancing cancer research and requires applicants to outline sustainability plans for the cohorts beyond the funding period while adhering to NIH data sharing policies. Interested applicants must submit their proposals by February 28, 2025, and can find additional information and application details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has issued a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts." This initiative aims to establish population-based cancer epidemiology cohorts that address knowledge gaps in cancer etiology and survivorship, with a focus on understudied populations. Eligible applicants include higher education institutions, nonprofits, and government entities, and proposed research should complement existing cohorts while fostering community engagement. Key objectives include methodologic development for participant recruitment and retention, incorporating innovative technologies, and ensuring adequate representation of diverse populations in research. Applicants must outline sustainability plans for the cohorts beyond the funding period and adhere to NIH data sharing policies, ensuring data accessibility for future research. The application process involves detailed instructions regarding eligibility, required registrations, and submission through Grants.gov. Review criteria focus on the significance of the research problem, qualification of the investigative team, innovative approaches, and the rationale behind the proposed methodologies. This grant reflects NIH's commitment to advancing cancer research by supporting studies that address emerging challenges and disparities in health outcomes.
    Similar Opportunities
    Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for research in established cancer epidemiology cohort studies under the U01 cooperative agreement mechanism. This initiative aims to support hypothesis-driven research utilizing data from cohorts that have achieved their initial recruitment goals, focusing on cohort maintenance, continuous follow-up, and resource sharing while addressing significant cancer control questions. The program encourages applications that leverage existing cohort data to explore understudied populations and cancer exposures, with no budget limits reflecting project needs and a maximum project duration of five years. Interested applicants must register with Grants.gov and adhere to NIH data-sharing policies, with the application deadline set for February 28, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the opportunity's webpage at http://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity for secondary analysis and integration of existing datasets to elucidate cancer risk and related outcomes. This initiative encourages innovative research that leverages existing clinical, genomic, and epidemiological data to address critical questions in cancer control, with a focus on risk prediction, survival, and treatment responses. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and foreign entities, with a budget cap of $275,000 over a two-year period. Applications are due by September 7, 2026, and interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-255.html.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for epidemiologic research on emerging risk factors associated with liver cancer, specifically hepatocellular carcinoma and other subtypes. This initiative aims to investigate both novel and established biological, environmental, and social risk factors that contribute to liver cancer development in the United States, with a focus on understanding the interplay of these factors. The funding is available through the Research Project Grant (R01) mechanism for projects lasting up to five years, and applications are encouraged from a diverse range of eligible applicants, including educational institutions and community organizations. Interested parties should note that the application deadline is May 7, 2025, and can find more information at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.